Supplementary Figures from Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring &lt;i&gt;MET&lt;/i&gt; Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical Models